Skip to main content
Top
Published in: The Patient - Patient-Centered Outcomes Research 2/2016

01-04-2016 | Original Research Article

Content Validity of the Hypogonadism Impact of Symptoms Questionnaire (HIS-Q): A Patient-Reported Outcome Measure to Evaluate Symptoms of Hypogonadism

Authors: Heather L. Gelhorn, Margaret K. Vernon, Katie D. Stewart, Michael G. Miller, Meryl Brod, Stanley E. Althof, Leonard R. DeRogatis, Adrian Dobs, Allen D. Seftel, Dennis A. Revicki

Published in: The Patient - Patient-Centered Outcomes Research | Issue 2/2016

Login to get access

Abstract

Background

Hypogonadism, or low testosterone, is a common disorder. There are currently no patient-reported outcome (PRO) instruments designed to comprehensively evaluate the symptoms of hypogonadism and to detect changes in these symptoms in response to treatment.

Objective

The purpose of this study was to develop a PRO instrument, the Hypogonadism Impact of Symptoms Questionnaire (HIS-Q) and to assess its content validity.

Methods

A literature review, expert clinician input, and qualitative concept elicitation with 39 male hypogonadism patients (four focus groups: n = 25; individual interviews: n = 14; mean age 52.3 ± 14.3 years) from the USA were used to develop the draft HIS-Q. Subsequent cognitive interviews (n = 29; mean age 51.5 ± 15.4 years) were used to evaluate content validity.

Results

Emergent discussion with participants yielded symptoms within the sexual, physical, energy, sleep, cognition, and mood domains. Low libido and tiredness were most commonly reported. The initial version of the HIS-Q includes 53 items that were consistently understood by the participants, who found the instrument to be relevant to their experiences with hypogonadism and comprehensive in the content coverage of symptoms.

Conclusion

The HIS-Q is a comprehensive PRO measure of hypogonadism symptom severity in males. Its design elements, including the response options and recall period, were suitable, and content validity was confirmed.
Appendix
Available only for authorised users
Literature
1.
go back to reference Araujo AB, Esche GR, Kupelian V, O’Donnell AB, Travison TG, Williams RE, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241–7.CrossRefPubMed Araujo AB, Esche GR, Kupelian V, O’Donnell AB, Travison TG, Williams RE, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241–7.CrossRefPubMed
2.
go back to reference Seftel A. Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis. Int J Impot Res. 2006;18(3):223–8.CrossRefPubMed Seftel A. Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis. Int J Impot Res. 2006;18(3):223–8.CrossRefPubMed
3.
go back to reference Fleishman SB, Khan H, Homel P, Suhail MF, Strebel-Amrhein R, Mohammad F, et al. Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens. J Clin Oncol. 2010;28(34):5054–60.CrossRefPubMed Fleishman SB, Khan H, Homel P, Suhail MF, Strebel-Amrhein R, Mohammad F, et al. Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens. J Clin Oncol. 2010;28(34):5054–60.CrossRefPubMed
4.
go back to reference O’Connor DB, Corona G, Forti G, Tajar A, Lee DM, Finn JD, et al. Assessment of sexual health in aging men in Europe: development and validation of the European Male Ageing Study Sexual Function Questionnaire. J Sex Med. 2008;5(6):1374–85.CrossRefPubMed O’Connor DB, Corona G, Forti G, Tajar A, Lee DM, Finn JD, et al. Assessment of sexual health in aging men in Europe: development and validation of the European Male Ageing Study Sexual Function Questionnaire. J Sex Med. 2008;5(6):1374–85.CrossRefPubMed
5.
go back to reference Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822–30.CrossRefPubMed Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822–30.CrossRefPubMed
6.
go back to reference Lee KK, Berman N, Alexander GM, Hull L, Swerdloff RS, Wang C. A simple self-report diary for assessing psychosexual function in hypogonadal men. J Androl. 2003;24(5):688–98.CrossRefPubMed Lee KK, Berman N, Alexander GM, Hull L, Swerdloff RS, Wang C. A simple self-report diary for assessing psychosexual function in hypogonadal men. J Androl. 2003;24(5):688–98.CrossRefPubMed
7.
go back to reference Rosen RC, Araujo AB, Connor MK, Elstad EA, McGraw SA, Guay AT, et al. Assessing symptoms of hypogonadism by self-administered questionnaire: qualitative findings in patients and controls. Aging Male. 2009;12(2–3):77–85.CrossRefPubMed Rosen RC, Araujo AB, Connor MK, Elstad EA, McGraw SA, Guay AT, et al. Assessing symptoms of hypogonadism by self-administered questionnaire: qualitative findings in patients and controls. Aging Male. 2009;12(2–3):77–85.CrossRefPubMed
8.
go back to reference Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49(9):1239–42.CrossRefPubMed Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49(9):1239–42.CrossRefPubMed
9.
go back to reference Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf). 2000;53(6):703–11.CrossRefPubMed Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf). 2000;53(6):703–11.CrossRefPubMed
10.
go back to reference Rosen RC, Araujo AB, Connor MK, Gerstenberger EP, Morgentaler A, Seftel AD, et al. The NERI Hypogonadism Screener: psychometric validation in male patients and controls. Clin Endocrinol (Oxf). 2011;74(2):248–56.CrossRefPubMed Rosen RC, Araujo AB, Connor MK, Gerstenberger EP, Morgentaler A, Seftel AD, et al. The NERI Hypogonadism Screener: psychometric validation in male patients and controls. Clin Endocrinol (Oxf). 2011;74(2):248–56.CrossRefPubMed
11.
go back to reference Wiltink J, Beutel ME, Brahler E, Weidner W. Hypogonadism related symptoms: development and evaluation of an empirically derived self-rating instrument (HRS ‘Hypogonadism Related Symptom Scale’). Andrologia. 2009;41(5):297–304.CrossRefPubMed Wiltink J, Beutel ME, Brahler E, Weidner W. Hypogonadism related symptoms: development and evaluation of an empirically derived self-rating instrument (HRS ‘Hypogonadism Related Symptom Scale’). Andrologia. 2009;41(5):297–304.CrossRefPubMed
12.
go back to reference Heinemann LA, Saad F, Zimmermann T, Novak A, Myon E, Badia X, et al. The Aging Males’ Symptoms (AMS) Scale: update and compilation of international versions. Health Qual Life Outcomes. 2003;1:15.CrossRefPubMedPubMedCentral Heinemann LA, Saad F, Zimmermann T, Novak A, Myon E, Badia X, et al. The Aging Males’ Symptoms (AMS) Scale: update and compilation of international versions. Health Qual Life Outcomes. 2003;1:15.CrossRefPubMedPubMedCentral
13.
go back to reference Heinemann LA, Moore C, Dinger JC, Stoehr D. Sensitivity as outcome measure of androgen replacement: the AMS Scale. Health Qual Life Outcomes. 2006;4:23.CrossRefPubMedPubMedCentral Heinemann LA, Moore C, Dinger JC, Stoehr D. Sensitivity as outcome measure of androgen replacement: the AMS Scale. Health Qual Life Outcomes. 2006;4:23.CrossRefPubMedPubMedCentral
14.
go back to reference US Food and Drug Administration. Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Federal Regist. 2009;74(235):65132–3. US Food and Drug Administration. Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Federal Regist. 2009;74(235):65132–3.
15.
go back to reference Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 1—eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77.CrossRefPubMed Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 1—eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77.CrossRefPubMed
16.
go back to reference Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2—assessing respondent understanding. Value Health. 2011;14(8):978–88.CrossRefPubMed Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2—assessing respondent understanding. Value Health. 2011;14(8):978–88.CrossRefPubMed
17.
go back to reference Leidy NK, Vernon M. Perspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics. 2008;26(5):363–70.CrossRefPubMed Leidy NK, Vernon M. Perspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics. 2008;26(5):363–70.CrossRefPubMed
18.
go back to reference Heinemann LA, Zimmermann T, Vermeulen A, Thiel C, Hummel W. A new, aging males’ symptoms’ rating scale. Aging Male. 1999;2:105–14.CrossRef Heinemann LA, Zimmermann T, Vermeulen A, Thiel C, Hummel W. A new, aging males’ symptoms’ rating scale. Aging Male. 1999;2:105–14.CrossRef
20.
go back to reference Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJ, Saad F, Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. 2010;7(7):2572–82.CrossRefPubMed Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJ, Saad F, Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. 2010;7(7):2572–82.CrossRefPubMed
21.
go back to reference Moore C, Huebler D, Zimmermann T, Heinemann LA, Saad F, Thai DM. The Aging Males’ Symptoms Scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol. 2004;46(1):80–7.CrossRefPubMed Moore C, Huebler D, Zimmermann T, Heinemann LA, Saad F, Thai DM. The Aging Males’ Symptoms Scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol. 2004;46(1):80–7.CrossRefPubMed
22.
go back to reference Behre HM, Tammela TL, Arver S, Tolra JR, Bonifacio V, Lamche M, et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male. 2012;15(4):198–207.CrossRefPubMed Behre HM, Tammela TL, Arver S, Tolra JR, Bonifacio V, Lamche M, et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male. 2012;15(4):198–207.CrossRefPubMed
23.
go back to reference Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639–50.CrossRefPubMed Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639–50.CrossRefPubMed
25.
go back to reference Dobs AS, McGettigan J, Norwood P, Howell J, Waldie E, Chen Y. A novel testosterone 2 % gel for the treatment of hypogonadal males. J Androl. 2012;33(4):601–7.CrossRefPubMed Dobs AS, McGettigan J, Norwood P, Howell J, Waldie E, Chen Y. A novel testosterone 2 % gel for the treatment of hypogonadal males. J Androl. 2012;33(4):601–7.CrossRefPubMed
26.
go back to reference Gelhorn HL, Dashiell-Aje E, Miller MG, Brod M, DeRogatis LR, Dobs A, et al. Evaluation of the psychometric properties of the Hypogonadism Impact of Symptoms Questionnaire (HIS-Q). 2015 (In preparation). Gelhorn HL, Dashiell-Aje E, Miller MG, Brod M, DeRogatis LR, Dobs A, et al. Evaluation of the psychometric properties of the Hypogonadism Impact of Symptoms Questionnaire (HIS-Q). 2015 (In preparation).
Metadata
Title
Content Validity of the Hypogonadism Impact of Symptoms Questionnaire (HIS-Q): A Patient-Reported Outcome Measure to Evaluate Symptoms of Hypogonadism
Authors
Heather L. Gelhorn
Margaret K. Vernon
Katie D. Stewart
Michael G. Miller
Meryl Brod
Stanley E. Althof
Leonard R. DeRogatis
Adrian Dobs
Allen D. Seftel
Dennis A. Revicki
Publication date
01-04-2016
Publisher
Springer International Publishing
Published in
The Patient - Patient-Centered Outcomes Research / Issue 2/2016
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI
https://doi.org/10.1007/s40271-015-0138-8

Other articles of this Issue 2/2016

The Patient - Patient-Centered Outcomes Research 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.